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ABSTRACT
Graft rejection is a serious complication in cord blood transplantation (CBT), but little is known about the
mechanism of rejection. To investigate the potential role of T lymphocytes in graft rejection, we isolated
a CD81 cytotoxic T lymphocyte (CTL) clone of recipient origin from blood obtained from a patient with graft
rejection after CBT from anHLA-mismatched unrelated donor. The isolated CTL clone specifically recognized
an HLA-B*1501 molecule as an alloantigen, which was expressed in donor cells but not in recipient cells. The
results of a microchimerism analysis specific for HLA-B*1501 and a polymerase chain reaction assay specific for
the T cell receptor on DNA from pretransplant peripheral blood mononuclear cells revealed that the patient
was exposed to HLA-B*1501 prior to CBT, and that the CTL clone was in the patient’s blood prior to trans-
plantation. The present study demonstrates a potential role for pretransplant CTL in graft rejection following
CBT.
 2008 American Society for Blood and Marrow Transplantation
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Although cord blood transplantation (CBT) from
unrelated donors is an attractive treatment for patients
with hematologic disease [1-6], graft rejection is a seri-
ous complication and is associated with a high rate of
mortality [3,4,7,8]. The mechanisms of graft rejection
have been extensively studied in bone marrow trans-
plantation (BMT). One mechanism proposed by the
studies in human and animal models is an immuno-
logic response in which the host-derived T lympho-
cytes recognize donor-specific antigens [9-14]. For
CBT, however, the role of the host-derived T lympho-
cytes in graft rejection has never been demonstrated in
humans.
Here, we demonstrate a potential role of the host-
derived cytotoxic T lymphocytes (CTLs) for graft
rejection after CBT.MATERIALS AND METHODS
Study Patient
A 59-year-old woman with acute myelomonocytic
leukemia received CBT from an unrelated male donor.
The details of the CBT procedure and the clinical
course of the patient were reported previously [15].
Briefly, the preparative regimen consisted of 125 mg/m2
fludarabine and 180 mg/m2 melphalan, and 2.9 
107/kg nuclear cells were infused. White blood cell
(WBC) and neutrophil counts increased to 100/mL
and 60/mL, respectively, with 65% of donor chimerism
on day 16, but both counts subsequently decreased to
less than the detection limit of the autohemocytometer
on day 26. Graft rejection was diagnosed based on
severemarrow hypoplasia and a complete loss of donor
chimerism in bone marrow cells on day 28. A second397
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day 35. The infused nuclear cell dose was 2.9 107/kg.
DNA typing of the HLA-A, -B, and -DRB1 loci dem-
onstrated that the recipient was A*1101/A*2402,
B*4404/B*5603, and DRB1*1201/DRB1*1302, the
first CBT donor was A*1101/A*2402, B*1501/
B*5603, and DRB1*0901/DRB1*1201, and the second
CBT donor was A*2402/A*3303, B*4403/B*5101, and
DRB1*1201/DRB1*1302. The patient had HLA anti-
bodies, including those against HLA-A33, and broad
HLA-DR antigens prior to transplantation, whereas
HLA antibody against HLA-B*1501 was not detected.
Thepatient has one 19-year-old daughter.DNA typing
of the HLA-A, -B, and -DRB1 loci demonstrated that
her daughter was A*1101/A*2601, B*1501/B*5603,
and DRB1*0405/DRB1*1201.
Cell Culture
CTL clones were isolated from a blood sample as
described previously [16]. Briefly, peripheral blood
mononuclear cells (PBMCs) obtained from the patient
on day 20 were cultured in interleukin-2-containing
media without stimulator cells for 14 days, and T lym-
phocyte clones were isolated by limiting dilution.
Transfection and CTL Stimulation Assays
The patient’s B-LCL were transfected by electro-
poration with the pEAK10 plasmid (Edge BioSystems,
Gaithersburg, MD) encoding HLA-B*1501 cDNA,
selected for 3 days with 0.8 mg/mL of puromycin,
and assayed as a target for N19D8 CTL. Cytotoxicity
was determined using a chromium release assay [16].
Interferon-g release assays were conducted as pre-
viously described [16]. Briefly, COS cells were trans-
fected with a plasmid encoding HLA-B*1501, B*5603
(negative control), or B*4403 (negative control) cDNA
using the FuGENE transfection reagent (Roche, Indi-
anapolis, IN). COS transfectants were cocultured with
N19D8 CTL, and interferon-g production was mea-
sured in the supernatant after 24 hours using an
enzyme-linked immunosorbent assay (Endogen,
Pierce, Rockford, IL).
Polymerase Chain Reaction (PCR) Specific for the
T Cell Receptor
The T cell receptor Vb repertoire was determined
by flow cytometry using an IOTest Beta Mark Kit
(Beckman Coulter, Fullerton, CA). The nucleotide
sequences of the CTL clone’s uniquely rearranged T
cell receptor Vb chain gene were determined by direct
DNA sequencing of the amplified PCR product [17].
To determine the presence of the N19D8 clone-
specific T cell receptor rearrangement, nested PCR
was performed on genomic DNA extracted from
aCTL clone N19D8 and PBMCs using a T cell recep-
tor Vb17-specific primer set for the first PCR:
50-TTTCAGAAAGGAGATATAGCT-30 (sense) and50-TTCTGATGGCTCAAACAC-30 (antisense) fol-
lowed by a second primer set specific for the N19D8
clone T cell receptor: 50-GGAGATATAGCTGAAG
GGTA-30 (sense) and 50-CCCCGCAAAGCTCTCA-
30 (antisense). PCR products were sequenced and
confirmed to be identical in sequence to the N19D8-
specific T cell receptor rearrangement. The PCR was
performed with thermalcycler (Model 9600; Perkin-
Elmer, Boston, MA) for 35 cycles under the following
conditions: denaturation at 95C for 1 minute, primer
annealing at 55C for 1 minute, and primer extension
at 72C for 1 minute in the first step, and denaturation
at 95C for 1 minute, primer annealing at 67C for
15 seconds, and primer extension at 72C for 1 minute
in the second step. Each reaction contained 0.4 mL of
Advantage 2 Polymerase Mix (Clontech Laboratories
Inc., Palo Alto, CA).
Microchimerism Analysis
The presence of the microchimerism was deter-
mined using a nested PCR approach on genomic
DNA extracted from a fingernail sample and PBMCs
as previously described [18]. Briefly, nested PCR was
performed on genomicDNA using anHLA-B-specific
primer set for the first PCR: 50-GGCGGGGGCG
CAGGACCTGA-30 and 50-GGCGGGGGCGCAG
GACCCGG-30 (1:1 mixture; sense) and 50-GAGGC
CATCCCCGGCGACCTAT-30 (antisense) followed
by a second primer set specific for HLA-B*1501: 50-A
CCGGGAGACACAGATCTC-30 (sense) and 50-CT
TGCCGTCGTAGGCGG-30 (antisense). The touch-
down procedure [19] was performed as first-step PCR
under the following conditions: (1) denaturation at
96C for 20 seconds and primer annealing at 72C for
2 minutes for 5 cycles, (2) denaturation at 96C for
20 seconds and primer annealing at 70C for 2 minutes
for 5 cycles, (3) denaturation at 96C for 20 seconds and
primer annealing at 68C for 2mintues for 4 cycles, and
(4) denaturation at 96C for 20 seconds and primer
annealing at 72C for 2.15 minutes for 15 cycles. The
second-step PCR was performed for 28 cycles under
the following conditions: denaturation at 94C for
1 minute, primer annealing at 62C for 1 minte, and
primer extension at 72C for 1 minute. FastStart Taq
DNA Polymerase (Roche) and AmpliTaq Gold PCR
Master Mix (Applied Byosistems, Foster City, CA)
were used in the first- and the second-step PCR,
respectively.
RESULTS
Isolation of CTL Clone N19D8
Two CTL clones were isolated from the periph-
eral blood of the patient just after the onset of graft
rejection. One clone lysed B-LCL from the patient
but failed to lyse B-LCL from the donor of the first
CBT. The other clone, designated N19D8, lysed
Role of CTL in Graft Rejection after CBT 399B-LCL from the donor but not from the patient
(Figure 1A). Thus, we further investigated the
N19D8 clone because this clone had the possibility
of being involved in immunologic graft rejection.
Flow cytometry analysis and sex chromosome fluores-
cein in situ hybridization revealed that the N19D8
clone was a CD31CD42CD81 T cell and originated
from the patient (data not shown).
CTL Clone N19D8 Recognizes the HLA-B*1501
Molecule
In a cytotoxicity assay using a panel of B-LCL
derived from unrelated individuals, N19D8CTL lysed
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Figure 1. The N19D8 CTL clone recognizes HLA-B*1501. (A)
Transfection of HLA-B*1501 cDNA into the B-LCL from the
patient restored recognition by N19D8 CTL. The patient’s
B-LCL were transfected with a plasmid encoding HLA-B*1501
cDNA and assayed as a target for N19D8 CTL. Cytotoxicity was
determined using a chromium release assay. Lysis of the first-donor
B-LCL (closed squares), second-donor B-LCL (open squares),
patient B-LCL (triangles), and HLA-B*1501-transfected patient
B-LCL (circles) are shown as the mean of triplicate cultures at vari-
ous E:T ratios. (B)HLA-B*1501 cDNA stimulated interferon-g pro-
duction by N19D8 CTL. COS cells were transfected with a plasmid
encodingHLA-B*1501, B*5603 (negative control), or B*4403 (nega-
tive control) cDNA. COS transfectants were cocultured with
N19D8 CTL, and interferon-g production was measured in the
supernatant, an enzyme-linked immunosorbent assay. Data is shown
as the mean of triplicate determinations.all of 4 B-LCL lines from unrelated individuals that
shared HLA-B*1501 but failed to lyse B-LCL from
the donor of the second CBT and 7 unrelated individ-
uals without B*1501 (Table 1). These results indicated
that N19D8 CTL recognized the HLA-B*1501 mole-
cule as an alloantigen, which was only expressed in
donor cells, or a minor histocompatibility antigen
presented by HLA-B*1501 molecule.
To determine if the lack of recognition by N19D8
CTLwas solely because of the absence ofHLA-B*1501
gene expression, the patient’s B-LCL were transfected
with HLA-B*1501 cDNA and used as a target in cyto-
toxicity assays.TheB*1501-transfected patient B-LCL
was lysed almost as well as the first CBT donor’s B-
LCL (Figure 1A). Furthermore, COS cells transfected
withHLA-B*1501 cDNA alone stimulated interferon-
g production by N19D8 CTL (Figure 1B). Thus, we
concluded that the N19D8 CTL clone recognizes
mismatched HLA-B*1501 as an alloantigen.
The Presence of the N19D8 CTL Clone and HLA-
B*1501 Microchimerism Prior to Transplantation
We next determined whether the N19D8 clone
developed prior to transplantation using nested PCR
assays specific for theCTLclone’s uniquely rearranged
T cell receptor Vb17 chain gene. PCR products were
detected by amplification of DNA from pretransplant
as well as posttransplant PBMCs (Figure 2), demon-
strating that the N19D8 CTL clone developed in the
patient prior to the first CBT. We further tested
pretransplant PBMCs for chimeric cells with the
HLA-B*1501 gene using PCR. Indeed, the HLA-
B*1501 microchimerism was detected by amplification
of DNA from the pretransplant patient PBMCs using
standardPCRaswell as nestedPCR (Figure 3), indicat-
ing that the patient was exposed to HLA-B*1501 prior
to CBT. The HLA-A*2601 microchimerism was also
detected from the pretransplant patient PBMCs.
From the patient PBMCs 3 months after transplanta-
tion, HLA-A*2601 and HLA-B*1501 microchimer-
isms were detected (data not shown).
DISCUSSION
Although direct verification would be difficult, it is
reasonable to conclude that the N19D8 clone was
involved in the graft rejection based on the following
clinical and laboratory findings. First, the patient
rejected the first cord blood graft with HLA-B*1501,
whereas the second graft without B*1501 was success-
fully engrafted. This clinical course is consistent with
allo-activity of the N19D8 clone. Second, CD31
CD42CD81 T lymphocytes accounted for the major-
ity of the lymphocytes in the patient’s blood just after
the onset of graft rejection (84.8%, data not shown).
Third, no clones that recognize the other mismatched
HLA antigens or minor histocompatibility antigens
400 H. Narimatsu et al.Table 1. Cytotoxicity Assays for N19D8 CTL against B-LCL
Characteristics of B-LCL
B-LCL HLA-A HLA-B Sex Lysis by CTL (%)*
Recipient B-LCL A*1101 A*2402 B*4403 B*5603 Female 0
First-donor B-LCL A*1101 A*2402 B*1501 B*5603 Male 36
Second-donor B-LCL A*2402 A*3303 B*4403 B*5101 Female 0
L11 A*0201 A*1101 B*1501 Female 34
L17 A*2402 A*3303 B*1501 B*4403 Male 35
L79 A*2402 A*3303 B*1501 B*4403 NA 42
JMD A*0201 A*2901 B*1501 B*4403 NA 44
L16 A*1101 A*2402 B*5401 B*5101 Male 0
L19 A*2402 A*3303 B*0702 B*4403 Male 0
L25 A*1101 A*2402 B*5401 B*5201 Female 0
L59 A*2603 A*3303 B*3501 B*4403 Male 0
L73 A*0201 A*2402 B*0702 B*6701 Female 0
L74 A*1101 A*3303 B*4002 B*5101 Female 0
RAR A*2901 A*3101 B*2705 B*4403 NA 0
NA indicates not available.
*E:T ratio was 10:1.were isolated by the limiting dilution cloning from the
patient just after the onset of graft rejection; N19D8
was the only clone with cytotoxic activity against the
first donor cells. Last, the patient developed graft
loss with a transient lymphocyte increase after reach-
ing transient mix chimerism. It is difficult to differen-
tiate immunologic graft rejection from other causes of
graft failure in CBT [7]; however, this clinical course is
consistent with those of patients who developed im-
munologic graft rejection following myeloablative or
nonmyeloablative BMT [14,20]. Taken together, the
results described above support the involvement of im-
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Figure 2. Presence of the N19D8 clone in pretransplant peripheral
blood from the patient. Detection of lymphocytes with the N19D8
clone-specific T cell receptor in pretransplant PBMCs. Nested
PCR was performed on genomic DNA using a T cell receptor
Vb17-specific primer set for the first PCR. Genomic DNA was
prepared from PBMCs obtained from the patient 1 month before
the first CBT (pre PBMCs) and 3 or 9 months after the second
CBT (post PBMCs). Genomic DNA from the N19D8 clone was
used as a positive control. Genomic DNA prepared from PBMCs
obtained from unrelated volunteers were used as negative controls.
PCR to detect b-globin was used as an internal control in each assay.munologic mechanisms such as cytotoxicity of T lym-
phocyte in the graft rejection.
The following routes of exposure of the patient to
HLA-B*1501 can be considered. One possibility is
that the patient was exposed to HLA-B*1501 during
her pregnancy; her 19-year-old daughter has HLA-
B*1501, presumably as an inherited paternal allele. It
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Figure 3. Presence of the N19D8 clone in pretransplant peripheral
blood from the patient. The presence of HLA-B*1501 microchimer-
ism in pretransplant PBMCs. Lanes 1 and 6 are standard PCRs
specific for HLA-B*1501 on genomic DNA from pretransplant
PBMCs from the patient and B*1501-positive PBMCs from the
patient’s daughter (positive control), respectively. Lanes 2-3, 4-5,
and 7-8 are nested PCR specific for HLA-B*1501 on diluted (in
parentheses) first PCR products from a posttransplant fingernail
sample from the patient (negative control), pretransplant PBMCs
from the patient, and PBMCs from the patient’s daughter (positive
control), respectively. PCR to detect complement factor 4 was used
as an internal control in each assay.
Role of CTL in Graft Rejection after CBT 401is known that fetal hematopoietic chimerism can per-
sist for decades, maintaining a paternal-specific CTL
developed during pregnancy over a long period of
time [21,22]. Another possibility is exposure via blood
transfusions. The patient had previously received
blood transfusions from random donors, and develop-
ment of HLA-B*1501-specific CTL as a consequence
of contamination by HLA-B*1501-positive WBCs in
the transfusion products cannot be completely ruled
out. Future studies are needed to determine which of
these events was related to graft rejection. It is to be
noted that the presence of an HLA-B*1501 microchi-
merism was demonstrated even after the onset of the
graft rejection. Although the mechanism is uncertain,
the N19D8 CTL clone might not be able to com-
pletely eliminate B*1501-positive cells. Further studies
focusing on this basic mechanism are warranted.
Interestingly, the patient had the HLA antibodies
including those against the second donor HLA,
HLA-A*3303, whereas the patient did not have the
HLA antibody against HLA-B*1501. This suggested
that HLA-antibodies did not have clinical impact on
the graft rejection in this patient. However, it is incon-
sistent with the previous studies in solid organ trans-
plantations or bone marrow transplantations [23,24].
This inconsistency indicates the clinical impact of
HLA antibodies is controversial in CBT. Future stud-
ies would allow a proper interpretation.
In conclusion, the results of the present study dem-
onstrate a potential role for pretransplant CTL in graft
rejection following CBT. Further studies focusing on
mismatched HLA-specific CTLs should help to estab-
lish an optimal strategy for overcoming graft rejection
in CBT.
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